Assistant Professor of Ophthalmology, Part-time
Movement disorders : official journal of the Movement Disorder Society
Myasthenia gravis after botulinum toxin A for Meige syndrome. Mov Disord. 2000 Jul; 15(4):736-8.
Myasthenia gravis after botulinum toxin A for Meige syndrome.
Borodic GE, Townsend DJ, Beyer-Machule CK
Ophthalmic plastic and reconstructive surgery
Dermis fat graft in eviscerated sockets. Ophthalmic Plast Reconstr Surg. 1989; 5(2):144-9.
Dermis fat graft in eviscerated sockets.
Antibodies to botulinum toxin. Ophthalmology. 1994 Jul; 101(7):1158-9.
Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
Orbicularis oculi myo-osseous fixation: a new treatment for benign essential blepharospasm and blepharospasm associated with diffuse facial dystonia (meige syndrome). Ophthalmic Surg Lasers Imaging. 2010 May-Jun; 41(3):360-9.
Orbicularis oculi myo-osseous fixation: a new treatment for benign essential blepharospasm and blepharospasm associated with diffuse facial dystonia (meige syndrome).
Treatment of myofascial pain with botulinum A toxin. Anesthesiology. 1994 Mar; 80(3):705-6.
Treatment of myofascial pain with botulinum A toxin.
Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthalmic Plast Reconstr Surg. 2006 May-Jun; 22(3):239-40.
Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides.
Multiple daily insulin injections in the treatment of diabetic retinopathy. The Job study revisited. Diabetes. 1978 May; 27(5):592-6.
Multiple daily insulin injections in the treatment of diabetic retinopathy. The Job study revisited.
Calderone JP, Chess J, Borodic G, Albert DM
Intraocular pathology of trisomy 18 (Edwards's syndrome): report of a case and review of the literature. Br J Ophthalmol. 1983 Mar; 67(3):162-9.
Intraocular pathology of trisomy 18 (Edwards's syndrome): report of a case and review of the literature.
Pearce LB, Borodic GE, First ER, MacCallum RD
Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol. 1994 Sep; 128(1):69-77.
Measurement of botulinum toxin activity: evaluation of the lethality assay.
Borodic G, Johnson E, Goodnough M, Schantz E
Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996 Jan; 46(1):26-9.
Botulinum toxin therapy, immunologic resistance, and problems with available materials.
New concepts in botulinum toxin therapy. Drug Saf. 1994 Sep; 11(3):145-52.
New concepts in botulinum toxin therapy.
Borodic GE, Pearce LB, Smith KL, Phelan M, Ferrante R
Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthalmic Plast Reconstr Surg. 1993; 9(3):182-90.
Botulinum B toxin as an alternative to botulinum A toxin: a histologic study.
Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001 Aug; 10(8):1531-44.
Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects.
Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. Plast Reconstr Surg. 1991 Feb; 87(2):285-9.
Botulinum A toxin for the treatment of adult-onset spasmodic torticollis.
Therapeutic botulinum toxin. Lancet. 1994 Nov 12; 344(8933):1370.
Facial plastic surgery clinics of North America
Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications. Facial Plast Surg Clin North Am. 2007 Feb; 15(1):11-6, v.
Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications.
Professor of Otolaryngology Head and Neck Surgery
John Hedley-Whyte Professor of Anaesthesia
William and Elizabeth Sweet Distinguished Professor of Neuroscience in the Department of Neurosurgery
Professor of Otolaryngology Head and Neck Surgery, Emeritus
Toxicon : official journal of the International Society on Toxinology
Botulinum toxin type A in multimodal management of age-related macular degeneration and related diseases. Toxicon. 2023 Dec; 236:107170.
Botulinum toxin type A in multimodal management of age-related macular degeneration and related diseases.
Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression". Ophthalmic Plast Reconstr Surg. 2013 May-Jun; 29(3):241.
Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".
Use of fillers as adjunct therapy for the treatment of lower face hemifacial spasm. Ophthalmic Plast Reconstr Surg. 2013 May-Jun; 29(3):225-6.
Use of fillers as adjunct therapy for the treatment of lower face hemifacial spasm.
Borodic GE, Caruso P, Acquadro M, Chick S
Parry-Romberg syndrome vasculopathy and its treatment with botulinum toxin. Ophthalmic Plast Reconstr Surg. 2014 Jan-Feb; 30(1):e22-5.
Parry-Romberg syndrome vasculopathy and its treatment with botulinum toxin.
Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg. 2014 Jan-Feb; 30(1):83.
Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression.
Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol. 1992 Jun; 12(2):121-7.
Effects of repeated botulinum toxin injections on orbicularis oculi muscle.
Hayashi N, Borodic G, Karesh JW, Tolentino MJ, Remulla HD, Van Wesep RA, Grossniklaus HE, Jakobiec FA, Green WR
Giant cell angiofibroma of the orbit and eyelid. Ophthalmology. 1999 Jun; 106(6):1223-9.
Giant cell angiofibroma of the orbit and eyelid.
Borodic G, Bartley M, Slattery W, Glasscock M, Johnson E, Malazio C, Goodnough M, Acquadro M, McKenna M
Botulinum toxin for aberrant facial nerve regeneration: double-blind, placebo-controlled trial using subjective endpoints. Plast Reconstr Surg. 2005 Jul; 116(1):36-43.
Botulinum toxin for aberrant facial nerve regeneration: double-blind, placebo-controlled trial using subjective endpoints.
Botulinum toxin efficacy for the treatment of pain. J Clin Anesth. 2005 Aug; 17(5):328-30.
Botulinum toxin efficacy for the treatment of pain.
Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg. 1992 Dec; 90(6):972-7; discussion 978-9.
Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry.
Borodic GE, Cozzolino D, Ferrante R, Wiegner AW, Young RR
Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. Ophthalmic Plast Reconstr Surg. 1991; 7(1):54-60.
Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy.
Botulinum A toxin for (expressionistic) ptosis overcorrection after frontalis sling. Ophthalmic Plast Reconstr Surg. 1992; 8(2):137-42.
Botulinum A toxin for (expressionistic) ptosis overcorrection after frontalis sling.
Borodic GE, Ferrante R, Wiegner AW, Young RR
Treatment of spasticity with botulinum toxin. Ann Neurol. 1992 Jan; 31(1):113.
Treatment of spasticity with botulinum toxin.
Myasthenic crisis after botulinum toxin. Lancet. 1998 Dec 05; 352(9143):1832.
Myasthenic crisis after botulinum toxin.
Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA
A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007 Oct 16; 581(25):4803-8.
A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies.
Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ
Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck. 1990 Sep-Oct; 12(5):392-9.
Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread.
Borodic GE, Duane D, Pearce B, Johnson E
Antibodies to botulinum toxin. Neurology. 1995 Jan; 45(1):204.
Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast Reconstr Surg. 1989 Mar; 83(3):546-54.
Blepharospasm and its treatment, with emphasis on the use of botulinum toxin.
Borodic GE, Gragoudas ES, Edward WO, Brockhurst RJ
Archives of ophthalmology (Chicago, Ill. : 1960)
Peripapillary subretinal neovascularization and serous macular detachment. Association with congenital optic nerve pits. Arch Ophthalmol. 1984 Feb; 102(2):229-31.
Peripapillary subretinal neovascularization and serous macular detachment. Association with congenital optic nerve pits.
Functional significance of fat surrounding the orbicularis oculi muscle. Ophthalmic Plast Reconstr Surg. 2010 Nov-Dec; 26(6):501-2.
Functional significance of fat surrounding the orbicularis oculi muscle.
Desmoplastic trichoepithelioma: report of a unique periocular case. Ophthalmic Plast Reconstr Surg. 2012 Sep-Oct; 28(5):e121-3.
Desmoplastic trichoepithelioma: report of a unique periocular case.
Borodic GE, Beyer-Machule CK, Millin J, Conte J, Foster CS
Immunoglobulin deposition in localized conjunctival amyloidosis. Am J Ophthalmol. 1984 Nov; 98(5):617-22.
Immunoglobulin deposition in localized conjunctival amyloidosis.
Pearce LB, Borodic GE, Johnson EA, First ER, MacCallum R
The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon. 1995 Feb; 33(2):217-27.
The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin.
Journal of the Royal Society of Medicine
Botulinum toxin potency: a mystery resolved by the median paralysis. J R Soc Med. 1994 Sep; 87(9):571-2.
Botulinum toxin potency: a mystery resolved by the median paralysis.
International journal of radiation oncology, biology, physics
Long-term follow-up of patients undergoing definitive radiation therapy for sebaceous carcinoma of the ocular adnexae. Int J Radiat Oncol Biol Phys. 1996 Mar 15; 34(5):1189-90.
Long-term follow-up of patients undergoing definitive radiation therapy for sebaceous carcinoma of the ocular adnexae.
Borodic GE, Ferrante R, Pearce LB, Smith K
Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord. 1994 Jan; 9(1):31-9.
Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections.
Borodic GE, Pearce LB, Cheney M, Metson R, Brownstone D, Townsend D, McKenna M
Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg. 1993 May; 91(6):1042-5.
Botulinum A toxin for treatment of aberrant facial nerve regeneration.
Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg. 2011 Jul-Aug; 27(4):e87-8.
Drug-induced graves disease from CTLA-4 receptor suppression.
Ma L, Jakobiec FA, Wolkow N, Dryja TP, Borodic GE
Multiple Eyelid Cysts (Apocrine and Eccrine Hidrocystomas, Trichilemmal Cyst, and Hybrid Cyst) in a Patient With a Prolactinoma. Ophthalmic Plast Reconstr Surg. 2018 May/Jun; 34(3):e83-e85.
Multiple Eyelid Cysts (Apocrine and Eccrine Hidrocystomas, Trichilemmal Cyst, and Hybrid Cyst) in a Patient With a Prolactinoma.
Botulinum toxin: death versus localized denervation. J R Soc Med. 1995 Apr; 88(4):239-40.
Botulinum toxin: death versus localized denervation.
Dose standardisation of botulinum toxin. Lancet. 1994 Apr 23; 343(8904):1035.
Dose standardisation of botulinum toxin.
The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 2002 Feb; 3(1):21-7.
The use of botulinum toxin for the treatment of chronic facial pain.
Diplopia after cataract surgery using 4% lidocaine in the absence of Wydase (sodium hyaluronidase) J Clin Anesth. 1999 Nov; 11(7):615-6.
Diplopia after cataract surgery using 4% lidocaine in the absence of Wydase (sodium hyaluronidase)
Borodic GE, Pearce LB, Smith K, Joseph M
Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck. 1992 Jan-Feb; 14(1):33-7.
Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle.